serotonin 5-HT2A antagonism
Vanda Wins FDA Nod for BYSANTI, a New Antipsychotic Tablet
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has announced FDA approval of BYSANTI™ (milsaperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. BYSANTI™ is a new chemical entity in the atypical antipsychotic class, offering patients and providers a novel therapeutic option with a…
